Clinical Trials Logo

Other clinical trials

View clinical trials related to Other.

Filter by:
  • Approved for marketing  
  • « Prev · Page 4

NCT ID: NCT01825395 Approved for marketing - Clinical trials for Lambert Eaton Myasthenic Syndrome

Use of 3,4-Diaminopyridine in the Treatment of Lambert-Eaton Syndrome

3 4-DAP
Start date: n/a
Phase:
Study type: Expanded Access

To learn more about the effect of 3, 4-Diaminopyridine (3,4-DAP) on patient diagnosed with Lambert-Eaton myasthenic syndrome (LEMS).

NCT ID: NCT01606982 Approved for marketing - Clinical trials for Metastatic Castration-Resistant Prostate Cancer

Provide Expanded Access to MDV3100 and Monitor Its Safety in Patients With Progressive Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy

Start date: n/a
Phase: N/A
Study type: Expanded Access

The purpose of this treatment protocol is to provide expanded access to MDV3100 and monitor its safety in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel-based chemotherapy.

NCT ID: NCT01592136 Approved for marketing - Clinical trials for Chronic Myeloid Leukemia (CML)

Expanded Access Program of Ponatinib

Start date: n/a
Phase: N/A
Study type: Expanded Access

This protocol will allow expanded access of ponatinib to patients ≥18 years with chronic myeloid leukemia (CML) any phase or Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ALL) who have failed all available treatment options.

NCT ID: NCT01412359 Approved for marketing - Clinical trials for Total Parenteral Nutrition-induced Cholestasis

Compassionate Use of Omegaven® in the Treatment of Parenteral Nutrition Associated Hepatic Injury

Start date: n/a
Phase:
Study type: Expanded Access

The overall purpose of this study is to determine if replacing standard soybean oil based fat emulsions with Omegaven®, a fish oil based fat emulsion, can reverse or prevent the progression of parenteral nutrition associated cholestasis. It is a compassionate use protocol for patients who already have significant cholestasis related to parenteral nutrition.

NCT ID: NCT00889135 Approved for marketing - Clinical trials for Dopamine Beta Hydroxylase (DBH) Deficiency

Long Term Treatment With L-DOPS

Start date: September 2004
Phase: N/A
Study type: Expanded Access

This study is designed to supply L-DOPS (droxidopa) on a long term basis to patients with a genetic form of profound orthostatic hypotension, most commonly DBH deficiency. It also allows us to collect medical history information on this small population of patients that would allow us to determine if there are any complications from this type of treatment.

NCT ID: NCT00872950 Approved for marketing - Clinical trials for Congenital Myasthenic Syndrome

3,4-Diaminopyridine Use in Lambert-Eaton Myasthenic Syndrome(LEMS) and Congenital Myasthenic Syndromes (CMS)

LEMS
Start date: n/a
Phase:
Study type: Expanded Access

The purpose of this study is to determine the effectiveness and adverse effects of 3,4-diaminopyridine for the treatment of the Lambert-Eaton Myasthenic Syndrome (LEMS) and Congenital Myasthenic Syndromes (CMS).

NCT ID: NCT00683306 Approved for marketing - Clinical trials for Non Small Cell Lung Cancer (NSCLC)

Open Label Extension Study With Gefitinib (IRESSA™) for Completing Trial Patients Who May Benefit From Further Treatment

Start date: n/a
Phase:
Study type: Expanded Access

The purpose of this study is to provide gefitinib treatment to patients who, on completion or closure of other gefitinib clinical studies, were either receiving placebo treatment, or are continuing on the same dose and regimen of gefitinib established in their preceding study, for as long as the patients continue to derive benefit.

NCT ID: NCT00499720 Approved for marketing - Cystic Fibrosis Clinical Trials

Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis and Pseudomonas Aeruginosa Airway Infection

Start date: n/a
Phase: N/A
Study type: Expanded Access

The primary objective of this program is to provide expanded access to aztreonam lysine for inhalation (AZLI) 75 mg prior to its commercial availability to patients with cystic fibrosis (CF) and chronic P. aeruginosa airway infection who have limited treatment options and are at risk for disease progression.